Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q96FJ2

UPID:
DYL2_HUMAN

ALTERNATIVE NAMES:
8 kDa dynein light chain b; Dynein light chain LC8-type 2

ALTERNATIVE UPACC:
Q96FJ2; B2R5B4

BACKGROUND:
The protein Dynein light chain 2, cytoplasmic, with alternative names such as 8 kDa dynein light chain b and Dynein light chain LC8-type 2, is a key component of the cytoplasmic dynein 1 complex. It is involved in the intracellular movement of vesicles and organelles along microtubules, playing a pivotal role in cellular logistics. By potentially influencing the distribution of cytoskeletal structures, it underscores its importance in cellular architecture and function.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Dynein light chain 2, cytoplasmic offers a pathway to novel therapeutic avenues. Given its critical role in the transport mechanisms within cells and its impact on the cytoskeleton, targeting this protein could lead to innovative treatments for diseases linked to cellular transport and structure abnormalities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.